Huang Bo, Wang Wei-Dong, Wu Fang-Cai, Wang Xiao-Mei, Shao Bu-Qing, Lin Ying-Miao, Zheng Guo-Xing, Li Gui-Qiang, Liu Can-Tong, Xu Yi-Wei, Wang Xin-Jia
Department of Orthopedics, the Cancer Hospital of Shantou University Medical College, Shantou 515041 Guangdong, China.
Department of Orthopedics, the Second Affiliated Hospital of Shantou University Medical College, Shantou 515000 Guangdong, China.
J Bone Oncol. 2025 Apr 26;52:100683. doi: 10.1016/j.jbo.2025.100683. eCollection 2025 Jun.
Esophageal squamous cell carcinoma (ESCC) is a prevalent malignant tumor worldwide, and individuals with ESCC and bone metastasis (BM) often face a challenging prognosis. Our objective was to identify the risk and prognostic factors associated with BM in patients with ESCC and develop a nomogram for predicting Cancer-Specific Survival (CSS) which following the occurrence of BM.
We conducted a retrospective analysis of data pertaining to ESCC patients with BM registered in the Surveillance, Epidemiology, and End Results (SEER) database from 2010 to 2015, as well as those treated at a Chinese institution from 2006 to 2020. Significant prognostic factors for CSS were assessed through univariate and multivariate Cox regression analyses. Subsequently, a nomogram was developed utilizing the SEER database and externally validated using real-world evidence from a Chinese cohort.
A total of 266 patients from the SEER database and 168 patients from the Chinese cohort were included in the analysis. In the SEER cohort, multivariate analysis indicated that chemotherapy, radiotherapy, liver metastasis, brain metastasis, and sex were independent prognostic factors for ESCC with BM. The prognostic nomogram demonstrated areas under the ROC curve (AUCs) of 0.823, 0.796, and 0.800, respectively, for predicting 3-, 6-, and 12-month CSS. In the Chinese validation cohort, the nomogram exhibited acceptable discrimination (AUCs: 0.822, 0.763, and 0.727) and calibration ability.
The study developed a prognostic nomogram to predict CSS in ESCC patients with BM, which can help clinicians assess survival and make individualized treatment decisions.
食管鳞状细胞癌(ESCC)是全球一种常见的恶性肿瘤,患有ESCC和骨转移(BM)的个体通常面临具有挑战性的预后。我们的目标是确定ESCC患者中与BM相关的风险和预后因素,并开发一种列线图来预测BM发生后的癌症特异性生存(CSS)。
我们对2010年至2015年在监测、流行病学和最终结果(SEER)数据库中登记的ESCC合并BM患者的数据,以及2006年至2020年在中国一家机构接受治疗的患者的数据进行了回顾性分析。通过单因素和多因素Cox回归分析评估CSS的显著预后因素。随后,利用SEER数据库开发了一种列线图,并使用来自中国队列的真实世界证据进行外部验证。
分析共纳入了SEER数据库中的266例患者和中国队列中的168例患者。在SEER队列中,多因素分析表明化疗、放疗、肝转移、脑转移和性别是ESCC合并BM的独立预后因素。该预后列线图预测3个月、6个月和12个月CSS的ROC曲线下面积(AUC)分别为0.823、0.796和0.800。在中国验证队列中,该列线图表现出可接受的区分度(AUC:0.822、0.763和0.727)和校准能力。
本研究开发了一种预后列线图来预测ESCC合并BM患者的CSS,这有助于临床医生评估生存情况并做出个体化治疗决策。